1 Department of Radiology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
2 Present address: Frankston Hospital, 1 Hastings Rd, Frankston 3199, Victoria, Australia.
AJR Am J Roentgenol. 2018 May;210(5):1118-1122. doi: 10.2214/AJR.17.18674. Epub 2018 Apr 9.
Dynamic CT is increasingly used for preoperative localization of parathyroid adenomas, but concerns remain about the radiation effective dose of CT compared with that of Tc-sestamibi scintigraphy. The purpose of this study was to compare the radiation dose delivered by three-phase dynamic CT with that delivered by Tc-sestamibi SPECT/CT performed in accordance with our current protocols and to assess the possible reduction in effective dose achieved by decreasing the scan length (i.e., z-axis) of two phases of the dynamic CT protocol.
The effective dose of a Tc-sestamibi nuclear medicine parathyroid study performed with and without coregistration CT was calculated and compared with the effective dose of our current three-phase dynamic CT protocol as well as a proposed protocol involving CT with reduced scan length.
The median effective dose for a Tc-sestamibi nuclear medicine study was 5.6 mSv. This increased to 12.4 mSv with the addition of coregistration CT, which is higher than the median effective dose of 9.3 mSv associated with the dynamic CT protocol. Reducing the scan length of two phases in the dynamic CT protocol could reduce the median effective dose to 6.1 mSv, which would be similar to that of the dose from the Tc-sestamibi study alone.
Dynamic CT used for the detection of parathyroid adenoma can deliver a lower radiation dose than Tc-sestamibi SPECT/CT. It may be possible to reduce the dose further by decreasing the scan length of two of the phases, although whether this has an impact on accuracy of the localization needs further investigation.
动态 CT 越来越多地用于甲状旁腺腺瘤的术前定位,但与 Tc-sestamibi 闪烁扫描相比,其 CT 辐射有效剂量仍存在争议。本研究旨在比较我们现行方案下的三相动态 CT 与 Tc-sestamibi SPECT/CT 所带来的辐射剂量,并评估通过减少动态 CT 方案中两个相位的扫描长度(即 z 轴)来降低有效剂量的可能性。
计算 Tc-sestamibi 核医学甲状旁腺研究中进行和不进行同机 CT 配准的有效剂量,并与我们现行的三相动态 CT 方案以及涉及减少扫描长度的 CT 的方案的有效剂量进行比较。
Tc-sestamibi 核医学研究的中位有效剂量为 5.6 mSv。如果增加同机 CT 配准,有效剂量将增加至 12.4 mSv,高于动态 CT 方案的中位有效剂量 9.3 mSv。在动态 CT 方案中减少两个相位的扫描长度可将中位有效剂量降低至 6.1 mSv,与 Tc-sestamibi 研究单独使用的剂量相似。
用于检测甲状旁腺腺瘤的动态 CT 可提供比 Tc-sestamibi SPECT/CT 更低的辐射剂量。通过减少两个相位的扫描长度,可能进一步降低剂量,但这是否会影响定位的准确性仍需进一步研究。